BioTheranostics Raises $32M in Private Equity Financing; Will Spin Off From BioMérieux | GenomeWeb

NEW YORK (GenomeWeb) – BioTheranostics announced today that it has raised $32 million in a private equity financing round, and will be spun off from parent company BioMérieux as a result.

The financing round was led by MVM Life Science Partners, with participation from Canepa Advanced Healthcare Fund and HealthQuest Capital. BioMérieux will remain a minority shareholder in the newly independent company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.